October 28, 2011
Bayer HealthCare announced on October 26 the results of a PIII international, multicenter, randomized, double-blind, placebo-controlled clinical study for its investigational anticancer compound regorafenib (BAY73-4506). The trial conducted in patients with metastatic colorectal cancer (mCRC) whose disease has progressed after...read more